Compare JYNT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | GNLX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.2M | 133.0M |
| IPO Year | 2014 | 2022 |
| Metric | JYNT | GNLX |
|---|---|---|
| Price | $8.91 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $17.00 | ★ $17.25 |
| AVG Volume (30 Days) | 164.8K | ★ 199.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.93 | 9.47 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $117,696,356.00 | $8,000.00 |
| Revenue This Year | $12.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $100.78 | ★ N/A |
| Revenue Growth | ★ 15.49 | N/A |
| 52 Week Low | $7.50 | $2.29 |
| 52 Week High | $11.78 | $8.54 |
| Indicator | JYNT | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.73 | 45.57 |
| Support Level | $8.04 | $2.73 |
| Resistance Level | $9.53 | $3.00 |
| Average True Range (ATR) | 0.43 | 0.15 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 50.41 | 15.79 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.